Drug name - Zejula
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8436185 | GLAXOSMITHKLINE | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(6 years from now) | |
| US8071623 | GLAXOSMITHKLINE | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(8 years from now) | |
| CN101932572A | GLAXOSMITHKLINE | Pharmaceutically Acceptable Salts Of 2-{4-[(3S)-Piperidin-3-Yl]Phenyl}-2H-Indazole-7-Carboxamide |
Nov, 2016
(5 years ago) | |
| CN101415686A | GLAXOSMITHKLINE | Amide Substituted Indazole And Benzotriazole Derivatives As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Apr, 2027
(4 years from now) | |
| CN101415686B | GLAXOSMITHKLINE | Amide Substituted Indazole And Benzotriazole Derivatives As Poly (Adp-Ribose) Polymerase (Parp) Inhibitor |
Apr, 2027
(4 years from now) | |
| CN101578279B | GLAXOSMITHKLINE | Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Jan, 2028
(5 years from now) | |
| CN101578279A | GLAXOSMITHKLINE | Amide Substituted Indazoles As Poly(Adp-Ribose) Polymerase(Parp) Inhibitors |
Jan, 2028
(5 years from now) | |
| IN288260B | GLAXOSMITHKLINE | Amide Substituted Indazole And Benzotriazole Derivatives As Poly (Adpribose) Polymerase (Parp) Inhibitors |
Apr, 2027
(4 years from now) | |
| IN200808150P1 | GLAXOSMITHKLINE | Amide Substituted Indazole And Benzotriazole Derivatives As Poly (Adp-Ribose)Polymerase (Parp) Inhibitors |
Apr, 2027
(4 years from now) | |
| EP2007733B1 | GLAXOSMITHKLINE | Amide Substituted Indazole And Benzotriazole Derivatives As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Apr, 2027
(4 years from now) | |
| EP2007733A1 | GLAXOSMITHKLINE | Amide Substituted Indazole And Benzotriazole Derivatives As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Apr, 2027
(4 years from now) | |
| EP2336120B1 | GLAXOSMITHKLINE | Combinations Containing Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Jan, 2028
(5 years from now) | |
| EP2805945A1 | GLAXOSMITHKLINE | Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Jan, 2028
(5 years from now) | |
| EP2336120A1 | GLAXOSMITHKLINE | Combinations Containing Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Jan, 2028
(5 years from now) | |
| EP2805945B1 | GLAXOSMITHKLINE | Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Jan, 2028
(5 years from now) | |
| EP2109608A1 | GLAXOSMITHKLINE | Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Jan, 2028
(5 years from now) | |
| EP2109608B1 | GLAXOSMITHKLINE | Amide Substituted Indazoles As Poly(Adp-Ribose)Polymerase (Parp) Inhibitors |
Jan, 2028
(5 years from now) | |
| EP2240466B1 | GLAXOSMITHKLINE | Pharmaceutically Acceptable Salts Of 2-{4-[(3S)-Piperidin-3- Yl]Phenyl} -2H-Indazole-7-Carboxamide |
Jan, 2029
(6 years from now) | |
| EP2240466A1 | GLAXOSMITHKLINE | Pharmaceutically Acceptable Salts Of 2-{4-[(3S)-Piperidin-3- Yl]Phenyl} -2H-Indazole-7-Carboxamide |
Jan, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071579 | GLAXOSMITHKLINE | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(4 years from now) | |
| US8143241 | GLAXOSMITHKLINE | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(4 years from now) | |
| US8859562 | GLAXOSMITHKLINE | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(8 years from now) | |
| US11091459 | GLAXOSMITHKLINE | Niraparib compositions |
Mar, 2038
(15 years from now) | |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 100MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.